Objective
To assess phospholipase A2 isoforms during human and experimental acute necrotizing pancreatitis. Phospholipase A2 isoforms (group I, II, and IV) were examined in acute pancreatitis tissues in humans and rats to determine whether the exocrine pancreas itself is a source of these mediators.
Summary Background Data
Phospholipase A2 has important regulatory functions, especially in inflammation.
Methods
Using Northern blot analysis and immunohistochemistry, the expression and localization of phospholipase A2 isoforms were analyzed in pancreatic tissue obtained from 21 patients with acute necrotizing pancreatitis and in pancreatic tissues of rats with acute edematous and necrotizing pancreatitis. Rat samples were examined daily for 1 week.
Results
In human acute pancreatitis, phospholipase A2-I mRNA expression was 8.9-fold decreased. By contrast, phospholipase A2-II (7.8-fold) and phospholipase A2-IV (8.1-fold) mRNA levels were increased. By in situ hybridization, phospholipase A2-IV was found to be expressed in remaining acinar and ductal cells adjacent to the necrotic areas. Immunostaining revealed moderate to intense phospholipase A2-II immunoreactivity in remaining acinar and ductal cells next to the necrosis. In rat pancreatitis, phospholipase A2-II mRNA levels in the pancreas were unchanged in the early phase (8 hours) but markedly increased after 24 hours, with a fluctuating pattern until day 7.
Conclusions
Enhanced expression of phospholipase A2-II and A2-IV isoenzymes in human and experimental acute pancreatitis suggests that these enzymes play a role in modulating the inflammatory reaction in the pancreas. Because phospholipase A2-II and A2-IV mRNA was strongly present in remaining viable pancreatic acinar and ductal cells, the pancreas itself seems to be at least partly a source and a regulator of phospholipase A2-II-and A2-IV-dependent inflammatory reactions in acute pancreatitis.
Acute pancreatitis is a sudden inflammatory process; the patient typically has severe upper abdominal pain with elevated levels of pancreatic enzymes in the blood and urine. 1 The clinical course of this disease is either mild and self-limiting (edematous pancreatitis) or severe and lifethreatening (necrotizing pancreatitis), and the treatment of the latter continues to be a challenge to even the best clinicians. 2 Histomorphologically, acute pancreatitis is associated with varying degrees of inflammation and autodigestion.
Whereas acute edematous pancreatitis is characterized by interstitial edema and polymorphonuclear cell infiltration, in necrotizing pancreatitis fat necrosis, interstitial hemorrhage, and pancreatic acinar and duct cell necrosis are often noted. [3] [4] [5] [6] Phospholipase A2 is the key enzyme of the arachidonic acid metabolism generating substrates such as arachidonic acids, prostaglandins, leukotrienes, and epoxytrienoic acids, which are important elements in many biologic responses, including inflammation. The main function of phospholipase A2 is to catalyze the hydrolysis of the sn-2 fatty acyl chain of several phospholipid substrates to yield fatty acids and phospholipids, which are important substrates for prostaglandin, prostacyclin, thromboxane, and leukotriene synthesis. 7 Three major isoforms of phospholipase A2 have been identified in human cells. Two 14-kd low-molecular-weight phospholipase A2s and a high-molecular-weight phospholipase A2 (85 kd) have been distinguished. 5 The low-molecular-weight phospholipase A2s are classified into phospholipase A2 group I (pancreatic phospholipase A2-I) and phospholipase A2 group II (nonpancreatic, synovial, or platelet phospholipase A2-II). The high-molecular-weight phospholipase A2 is also known as group IV phospholipase A2 (cytosolic phospholipase A2-IV). Phospholipase A2-I is synthesized in and released from pancreatic acinar cells but is also detectable in the lung, spleen, kidney, and ovarian tissues. Thus, phospholipase A2-I seems to participate in many physiologic processes apart from the digestion of food. 8 -11 Phospholipase A2-II is present in human digestive organs, fibroblasts, chondrocytes, platelets, and synovial fluid. Studies on regulation of phospholipase A2-II have confirmed that inflammatory stimuli, such as cytokines, can induce and upregulate its gene expression. Increased phospholipase A2-II levels have been observed in a variety of inflamed sites, and these findings suggest that phospholipase A2-II is especially involved in inflammatory responses and host defense mechanisms. Phospholipase A2-IV is located mainly in the cytoplasm, and along with phospholipase A2-II it mediates the production of arachidonic acid and plays an important role in cellular signaling mechanisms. [12] [13] [14] [15] These data support the long-held belief that phospholipase A2 isoforms play an important role in severe inflammatory processes, including acute pancreatitis. Previous studies have reported high serum levels of phospholipase A2-I and A2-II in patients with acute pancreatitis and acute attacks of chronic relapsing pancreatitis. 16, 17 However, the exact source of phospholipase A2-II in acute pancreatitis has not been determined, and it has been postulated that it is derived mainly from inflammatory cells and extrapancreatic sources. A hint to the inflammatory origin of phospholipase A2-II is obtained from the observation that phospholipase A2-II correlates significantly with the severity of acute life-threatening diseases such as septic shock, peritonitis, and multiple injuries as well as with necrotizing pancreatitis. 18 -21 In the present study, we evaluated and compared the expression and localization of phospholipase A2-I, A2-II, and A2-IV in the pancreas of patients with acute necrotizing pancreatitis to determine whether phospholipase A2-II and A2-IV are also produced in the pancreas in addition to phospholipase A2-I, which would provide evidence that the pancreas itself is an important regulator of the inflammatory reaction in this disorder. Because the tissue expression of phospholipase A2 isoforms could not be evaluated in a time-dependent manner in humans, we also studied the time-dependent expression patterns of phospholipase A2-I and A2-II in tissue samples from rats with experimental edematous and necrotizing pancreatitis.
METHODS

Human Studies
Normal pancreatic tissue samples were obtained from 12 previously healthy multiorgan donors (six male donors and six female donors) through an organ donor program at the University of Bern. The median age was 43 years (range 14 -56) . Two of the organ donors had been receiving pressors, but histopathologic analysis revealed no morphologic alterations in these pancreases. Serum amylase levels of all donors were in the normal range.
Necrotizing pancreatitis tissue samples were obtained from 21 patients (6 women and 15 men) undergoing surgery for necrotizing pancreatitis. The median age was 51 years (range 29 -76). The median Ranson score was 5 (range 3-8). Pancreatic surgery was performed a median of 7 days (range 4 -34) after the onset of acute pancreatitis. The cause of acute pancreatitis was alcohol in seven patients, gallstones in seven patients, endoscopic retrograde cholangiopancreatography-induced in one patient, and hyperlipidemia in one patient. In five patients the cause could not be clarified. Standard histopathologic analysis of the necrotizing pancreatitis tissues revealed no morphologic differences between the different etiologic groups. Tissue samples were taken at the border between necrotic and nonnecrotic pancreatic regions. On removal, the tissues were immediately fixed in the operating room in either Bouin or paraformaldehyde solution for immunohistochemical and standard pathologic analysis. Histologic analysis revealed that approximately 90% of the tissue area of the necrotizing pancreatitis samples consisted of cells that appeared vital. Randomly selected tissue pieces destined for RNA extraction were frozen in liquid nitrogen and maintained at Ϫ80°C until use. Tissue samples from the organ donors and from the necrotizing pancreatitis samples were taken from the same anatomical regions of the pancreas to ensure comparability.
All the studies were approved by the Human Subjects Committee of the University of Bern, Switzerland.
Animal Studies
Approval for the experiments was obtained from the Animal Ethics Committee of the Canton of Bern, Switzerland. Male Wistar rats weighing 240 to 280 g were kept in single cages exposed to a light/dark cycle, with free access to chow and water. The animals were divided into four groups: the control group, the acute edematous pancreatitis group, the necrotizing pancreatitis group, and the sham pancreatitis group. After an overnight fast, all animals were preanesthetized with ether, followed by intramuscular injection of phenobarbital (Nembutal sodium solution; Abbott Laboratories, Baar, Lucerne) at a dosage of 2 mg/kg and buprenorphine (Temgesic, Roche, Reinach, Switzerland) 22 at a dosage of 6 g/kg to induce anesthesia and analgesia, respectively. A plastic catheter was placed in the external jugular veins of the animals receiving intravenous cerulein for induction of acute edematous pancreatitis, as well as in the jugular veins of the animals in the sham treatment group.
In the acute edematous pancreatitis group, acute edematous pancreatitis was induced by infusion of 10 g/kg cerulein (Takus, Farmitalia Carlo Erba, Bremen, Germany) at a flow rate of 0.9 mL/h intravenously for 4 hours, as described in previous studies. 23, 24 After induction of acute pancreatitis, the jugular vein catheter was removed. The animals (six per time point) were killed 4 hours, 8 hours, 1, 2, 3, 4, 5, 6, or 7 days after the completion of the cerulein infusion. The whole pancreatic gland was removed and immediately randomly fixed either for histology or frozen in liquid nitrogen for RNA extraction.
In the necrotizing pancreatitis group, a laparotomy was performed by a midline incision and the duodenal part of the pancreatic gland was exposed. The biliopancreatic duct was cannulated transmurally with a 27-gauge needle. The bile duct was clamped with a bulldog clamp proximal to the pancreas at the hilum of the liver and 2% taurocholate solution (sodium taurocholate; Sigma, St. Louis, MO) was infused under constant pressure (30 cm H 2 O) at the rate of 0.1 mL/100 g body weight, as described previously. 23 After the administration of taurocholate, the bile duct was unclamped and the needle removed. The abdominal wall was closed in two layers. The animals (six per time point) were killed 4 hours, 8 hours, 1, 2, 3, 4, 5, 6, or 7 days after the end of the taurocholate infusion, and the whole pancreatic gland was removed and randomly immediately fixed either for histology or frozen in liquid nitrogen.
In the control group, pancreatic tissue samples (n ϭ 8) were obtained from untreated rats. A median laparotomy was performed and the entire pancreas was removed and immediately fixed for histology or frozen in liquid nitrogen for RNA extraction.
In the sham group, rats were treated under the same conditions as described for experimental pancreatitis but received either an intravenous infusion of 0.9% saline instead of cerulein (sham treatment group for edematous pancreatitis) or an intraductal infusion of 0.9% saline instead of 2% sodium taurocholate (sham treatment group for necrotizing pancreatitis). The animals (n ϭ 4) were killed according to the same time schedule, and the pancreases were removed and stored as described for the pancreatitis groups.
In all four groups, tissue samples from the pancreatic head and the pancreatic tail were taken for histologic analysis. The tissues were fixed in Bouin or paraformaldehyde solution and embedded in paraffin. The tissue remnants were immediately frozen in liquid nitrogen and stored at Ϫ80°C for Northern blot analysis.
To quantify the histologic changes, two masked independent pathologists judged the tissue samples using a point score described by Spormann et al. 25 Four horizontal serial sections (4-m thick) were taken from each tissue block and stained with hematoxylin and eosin. Edema, inflamma-tory infiltration, fat necrosis, parenchymal necrosis, and hemorrhage were evaluated on an arbitrary scale without knowledge of the treatment received by the animal group. The scores for each histopathologic parameter were added, with a maximum obtainable score of 27.
Probe Preparation
The phospholipase A2-I cDNA probe consisted of a 542-base pair fragment of rat phospholipase A2-I cDNA, which cross-hybridizes with human phospholipase A2-I. 26 The human phospholipase A2-II cDNA probe consisted of an 830-base pair fragment of human phospholipase A2-II cDNA. 27 The rat phospholipase A2-II cDNA probe consisted of a 750-base pair fragment. These three probes were kindly provided by Dr. J. Ishizaki, Shionogi Research Laboratory, Osaka, Japan. The phospholipase A2-IV cDNA consisted of a 562-base pair fragment and was kindly provided by Dr. U. Tibes, Roche Molecular Biochemicals, Roche Diagnostics GmbH, Research Center Penzberg, Germany. 28 The 7S cDNA probe consisted of a 190-base pair fragment of the mouse 7S RNA, which cross-hybridizes with human 7S RNA. 27, 29 The cDNA probes were radiolabeled with (␣-32 P)dCTP (NEN Life Science Products, Inc. Boston, MA) using a random primer labeling system (Roche Diagnostics, Rotkreuz, Switzerland). Sense and antisense phospholipase A2-IV cRNA probes were linearized and transcribed using the Ribomax system (Promega, Zürich, Switzerland), resulting in digoxigenin-labeled sense and antisense riboprobes, as previously described. 27
Northern Blot Analysis
Northern blot analysis was carried out as previously described. 29, 30 Total RNA of human and rat tissues was extracted, size fractionated, electrotransferred onto nylon membranes, and cross-linked by ultraviolet irradiation. 29, 30 For hybridization, 32 P-labeled cDNA probes for phospholipase A2-I, phospholipase A2-II and 7S, and a digoxigeninlabeled cRNA probe for human phospholipase A2-IV were used. For the cDNA probes, the blots were prehybridized for 8 hours, hybridized at 42°C overnight, and washed at 55°C three times in 0.2ϫ sodium chloride-sodium citrate buffer (SSC) and 2% sodium dodecyl sulfate (SDS), as described previously. 29 For the digoxigenin-labeled human phospholipase A2-IV cRNA probe, the filters were prehybridized and hybridized overnight at 65°C and washed in 2ϫ SSC and 0.1% SDS at room temperature, followed by three washes at 68°C for 15 minutes in 0.1ϫ SSC and 0.1% SDS. Afterward, the filters were incubated in a blocking reagent for 30 minutes and in a blocking buffer containing antidigoxigenin alkaline phosphatase antibody, washed with maleic acid buffer for 15 minutes three times, and incubated with 25 mmol/L disodium 4-chloro-3-phenyl phosphate (CDP) Star (Roche Diagnostics).
All membranes were then exposed at Ϫ80°C to x-ray films with intensifying screens. The membranes were rehybridized with the 7S cDNA probe to assess equivalent RNA loading and transfer, as previously reported. 27, 29 The intensity of the radiographic bands was quantified by video densitometry (Biorad 620, Biorad Laboratories, Hercules, CA). 29, 30 In Situ Hybridization of Phospholipase A2-IV in Human Acute Pancreatitis
Because of the unavailability of phospholipase A2-IV antibodies, we performed in situ hybridization for localization of mRNA expression. 27 Tissue sections were deparaffinized, rehydrated, and incubated in 0.2 mol/L HCl for 20 minutes. After washing with 2ϫ SSC, the tissues were permeabilized with proteinase K (30 g/mL), fixed with 4% paraformaldehyde in phosphate-buffered saline, washed, prehybridized, and hybridized, as previously reported. 31 After hybridization, excess labeled cRNA probe was removed by washing in 2ϫ SSC and by RNase treatment with 100 U/mL RNase T1 and 0.2 g/mL RNase, DNase-free, and incubated with an antidigoxigenin antibody conjugated with alkaline phosphatase (Roche Diagnostics). 5-bromo-4chloro-3-indolyl phosphate and nitroblue tetrazolium (Sigma, Buchs, Switzerland) were used for color reaction. No signal was detectable when the sense probe was used for in situ hybridization in control experiments.
Immunohistochemistry in Human Acute Pancreatitis
Only antibodies for human phospholipase A2-I and A2-II, but not for rat phospholipase A2-I and A2-II, were available. The human antibodies were not cross-reactive with rat phospholipase A2-I and A2-II. Therefore, immunostaining could be performed only in human tissues. Consecutive 4-m paraffin-embedded tissue sections were subjected to immunostaining using the alkaline phosphatase technique. 32, 33 Tissue sections were submerged in TBS buffer (10 mmol/L Tris-HCl, pH 7.4) containing 0.1% Triton X-100. After treatment with hyaluronidase (1 mg/mL), the sections were incubated with 10% normal goat serum for 30 minutes to block nonspecific binding, followed by incubation with the specific antibodies (monoclonal antibody for human phospholipase A2-I and polyclonal antibody for human phospholipase A2-II were gifts from Dr. T.M. Nevalainen, Turku, Finland). 34, 35 Bound primary antibody was detected with biotinylated goat IgG antimouse or antirabbit secondary antibodies and a streptavidin-alkalinephosphatase complex. This was followed by incubation with phThloRED solution (Kirkegaard & Perry Laboratories, Gaithersburg, MD) as the substrate and counterstaining with hematoxylin. To ensure specificity of the immunostaining reactions, consecutive tissue sections were incubated either in the absence of the primary antibody or with nonimmunized mouse or rabbit IgG. In both cases, no immunostaining was detected. Histologic analysis of the immunohistochemical results was performed by two independent observers masked to patient status, followed by resolution of any differences by joint review and consultation with a third observer.
Statistical Analysis
Results are expressed as median and range or as mean Ϯ standard error of mean. For comparison, the Mann-Whitney test or the Student t test was used. Significance was defined as P Ͻ .05.
RESULTS
Human Studies
In the normal pancreatic tissue samples, moderate to strong expression of phospholipase A2-I mRNA was detectable. In contrast, phospholipase A2-I mRNA levels were markedly reduced in the acute necrotizing pancreatitis samples. Densitometric analysis revealed that phospholipase A2-I mRNA levels in acute necrotizing pancreatitis were 8.9-fold lower (P Ͻ .01) compared with normal controls. The opposite was found for phospholipase A2-II: phospholipase A2-II mRNA expression was low or not detectable in the normal pancreas, but levels were markedly increased in 76% of the acute pancreatitis samples. Comparison of the densitometric values revealed that phospholipase A2-II was 7.8-fold increased in acute pancreatitis compared with normal controls (P Ͻ .01) ( Fig. 1) . Figure 1 . Northern blot analysis of phospholipase A2-I, A2-II, and A2-IV mRNA in the normal human pancreas compared with human acute necrotizing pancreatitis. In acute necrotizing pancreatitis phospholipase A2-I mRNA levels were markedly reduced, whereas phospholipase A2-II and A2-IV mRNA levels were significantly increased. 7S hybridization was used to verify equivalent RNA loading. 
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The pattern of phospholipase A2-IV mRNA expression was similar to that of phospholipase A2-II. In the normal pancreas, only low or undetectable phospholipase A2-IV mRNA levels were present, whereas all acute necrotizing pancreatitis samples exhibited increased phospholipase A2-IV mRNA expression. Densitometry revealed that phospholipase A2-IV mRNA levels were 8.1-fold greater in acute necrotizing pancreatitis compared with normal controls (P Ͻ .01).
In the normal pancreas, faint phospholipase A2-IV mRNA signals were present in some acinar cells and some islet cells. In contrast, in acute necrotizing pancreatitis samples, the phospholipase A2-IV mRNA signal was in general increased. In areas with remaining pancreatic parenchyma adjacent to pancreatic necrosis, acinar and ductal cells exhibited moderate phospholipase A2-IV mRNA signals. Sense control hybridization failed to produce a specific hybridization signal (Fig. 2) .
In the normal human pancreas, moderate to strong phospholipase A2-I immunostaining was present in all acinar cells (Fig. 3) . Phospholipase A2-II immunostaining was visible in only a few acinar cells in the normal pancreas in a focal pattern. Acute necrotizing pancreatitis tissues exhibited markedly reduced phospholipase A2-I immunostaining in most of the remaining acinar cells. However, in certain areas next to necrotic tissue, phospholipase A2-I immunostaining was still detectable at moderate intensity, whereas areas with a similar histologic degree of damage were devoid of phospholipase A2-I immunostaining. Phospholipase A2-II immunoreactivity was strongly increased in acute necrotizing pancreatitis samples. Thus, moderate to strong phospholipase A2-II immunostaining was present in almost all remaining acinar cells and also in cells exhibiting duct-like structures. The strongest immunoreactivity for phospholipase A2-II was found in the remaining parenchymal cells adjacent to the pancreatic necrosis, whereas in areas farther from the necrosis, less phospholipase A2-II immunoreactivity was present.
Animal Studies
Histologic and molecular analysis revealed similar results in the control and the sham groups for both pancreatitis models, so the results of control and sham animals are combined.
Animals in the control and sham groups had a mean Spormann point score of 2.0 Ϯ 0.8 points.
Four and 8 hours after induction of acute edematous pancreatitis, the mean Spormann scores were 12.9 Ϯ 1.3 and 11.6 Ϯ 2.2, respectively. The highest Spormann score was observed 4 hours after the end of the cerulein infusion. Afterward, the histomorphologic severity of acute edematous pancreatitis decreased to 5.4 Ϯ 0.8 points on day 1, 5.2 Ϯ 1.2 points on day 2, 6.9 Ϯ 1.1 points on day 3, and 5.3 Ϯ 1.3 points on day 4. A second, less pronounced increase was observed on day 5 (9.5 Ϯ 0.6 points). On day 6 and day 7, the Spormann score decreased to 6.4 Ϯ 0.8 and 6.3 Ϯ 0.8 points, respectively.
Four hours, 8 hours, and 1 day after induction of acute necrotizing pancreatitis, the mean Spormann scores were 11.2 Ϯ 1.2, 11.4 Ϯ 1.4, and 14.7 Ϯ 0.7, respectively. The highest Spormann score was found 1 day after the taurocholate application. Afterward, the histomorphologic severity of acute pancreatitis decreased slightly to 10.2 Ϯ 1.3 In the normal pancreas of control and sham-treated rats, moderate levels of phospholipase A2-I mRNA were present. In the acute edematous pancreatitis group 4 and 8 hours after induction, phospholipase A2-I mRNA expression levels were 6.7-and 2.5-fold greater than in the control and sham-treated rats (Fig. 4 ). Between day 1 and day 4, phospholipase A2-I mRNA expression was slightly greater in treated rats versus the normal controls, whereas on days 5, 6, and 7, phospholipase A2-I mRNA expression increased 2.8-, 6.5-, and 5.3-fold above the expression levels of the normal controls. In the acute necrotizing pancreatitis group 4 and 8 hours after induction with taurocholate, phospholipase A2-I mRNA levels were 2.5-and 1.8-fold less than those of normal controls; levels were 3.6-fold increased over those of normal controls on day 1. Another slight increase over normal controls was found on day 4 (2.5fold), whereas on the other days phospholipase A2-I mRNA levels were similar to those of the normal controls.
Phospholipase A2-II mRNA expression increased after induction of acute edematous and acute necrotizing pancreatitis. In acute edematous pancreatitis, a biphasic peak expression pattern of phospholipase A2-II mRNA was found ( Fig. 5 ). Phospholipase A2-II mRNA expression levels peaked on day 1 (35-fold increase) and declined afterward to 6.1-fold and 7.3-fold increases above the controls on days 2 and 3, respectively. On day 4, the phospholipase A2-II mRNA levels decreased to normal levels; they increased again on day 5 (6.3-fold), day 6 (5.7-fold), and day 7 (5.2-fold). After induction of acute necrotizing pancreatitis, phospholipase A2-II mRNA levels also showed a biphasic peak expression pattern. The highest phospholipase A2-II mRNA levels were found on day 2 (26.1-fold increase), day 3 (56-fold increase), and day 4 (9.2-fold increase), with a sharp decrease on day 5. On day 6, phospholipase A2-II mRNA expression increased again 34fold over that of the controls.
DISCUSSION
One of the earliest events after tissue injury is the release of inflammatory mediators, which initiates many of the ensuing events. 35 Fulminant acute pancreatitis is a disease of complex origin that results in activation and release of proinflammatory cytokines. 36 Phospholipase A2s are key mediators in inflammatory reactions, and their presence is required for the generation of a variety of inflammatory mediators. 8, [37] [38] [39] [40] [41] [42] During the past 20 years, several studies 
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have shown increased catalytic activity of phospholipase A2s (ca-phospholipase A2) in the serum of experimental 43 and human 17 acute pancreatitis. However, it has been suggested that ca-phospholipase A2s in serum may be derived mainly from nonpancreatic origin, even in acute pancreatitis. 44 Further, in patients with acute necrotizing pancreatitis, serum phospholipase A2 activity correlates significantly with the concentration of phospholipase A2-II and with the severity of the disease. Moreover, the absence of enhanced phospholipase A2-II activity in the pancreas of ceruleininfused rats within 18 hours of observation seemed to support the hypothesis that phospholipase A2-II is probably derived from extraacinar and extrapancreatic origin. 18 Three major isoforms of phospholipase A2 have been cloned from human tissues and can be differentiated by their molecular weight, cellular localization, and distinct func-tions. 8, [37] [38] [39] [40] However, their physiologic and pathophysiologic roles-especially those of phospholipase A2-II and A2-IV-and their importance in acute pancreatic inflammation are poorly understood. Levels of the proinflammatory cytokines interleukin 6 and tumor necrosis factor ␣ are elevated during experimental acute pancreatitis, and their serum levels correlate well with the severity of local pancreatic destruction. Blockade of the cytokine cascade at the level of the interleukin 6 receptor before or soon after the induction of acute pancreatitis significantly attenuates the increase in these cytokines in the serum and is associated with decreased severity of necrotizing pancreatitis and reduced intrinsic pancreatic damage. 45, 46 Interestingly, both interleukin 1 and tumor necrosis factor ␣ induce the synthesis and release of phospholipase A2-II 35 and may therefore exert, at least in part, their proinflammatory activity through this enzyme. If this hypothesis is correct, phospholipase A2-II inhibition should attenuate inflammation. In this respect, it is apparent that phospholipase A2-II has . Phospholipase A2 mRNA expression was analyzed at 4 hours, 8 hours, and daily until the seventh day after the onset of pancreatitis. 7S hybridization was used to verify equivalent RNA loading. C1, C2: control rats; S1, S2: sham-treated rats. diverse biologic functions in host defense, in amplification of inflammatory reactions, and in the generation of lipid mediators. 35 Phospholipase A2-II may become active in the presence of additional agents such as lipid peroxidative agents, bactericidal/permeability-increasing protein, and others 47 that can loosen cellular permeability barriers, thus in the case of pancreatitis providing pancreatic enzymes with access to the interstitial space. Because intact cell surfaces are not an optimal substrate for phospholipase A2-II hydrolysis, an initiating membrane-perturbing event may have to occur before phospholipase A2-II can bind and catalyze cell membrane hydrolysis. However, it is also possible that some events related to phospholipase A2-II could induce the activation of cytosolic phospholipase A2, with subsequent eicosanoid release. 45 In this study, we investigated the expression of three phospholipase A2 isoforms in the course of acute pancreatitis in human subjects and in experimental pancreatitis in rats. Not surprisingly, phospholipase A2-I was present at high levels in the normal human pancreas and was markedly reduced in acute pancreatitis in humans and rats. The pattern of phospholipase A2-II in the human pancreas was opposite that of phospholipase A2-I. Only low levels of phospholipase A2-II mRNA expression and protein were detectable in the normal pancreas, but high levels were found in acute pancreatitis. Similar observations were made for phospholipase A2-IV mRNA.
Phospholipase A2-IV was first identified in mouse macrophages, but recent studies have described its presence also in platelets, granulocytes, and various other organs. 38 -40 It is normally located in the cytoplasm and contributes to the rapid release of arachidonic acid in many cellular systems. 38 -40 Arachidonic acid release and subsequent eicosanoid synthesis are both important mediators of inflammation; therefore, both phospholipase A2-II and A2-IV are key factors in inflammation, and their presence or absence controls the activation of several inflammatory cascades. 48, 49 Interestingly, phospholipase A2-II and A2-IV mRNA was mainly present in the remaining pancreatic acinar and ductal cells in human necrotizing pancreatitis tissues. This finding suggests that phospholipase A2-II serum levels, at least in part, might be derived from the inflamed pancreatic tissue. In addition, the high expression of phospholipase A2-II and A2-IV mRNA in pancreatitis parenchyma suggests that the pancreas itself produces a significant amount of these mediators during acute inflammation. These mediators seem to contribute to local disease severity, and their release into the circulation might influence and mediate systemic complications during this disease.
The findings in human necrotizing pancreatitis are supported by our experimental pancreatitis studies. Phospholipase A2-II mRNA expression was markedly upregulated in the pancreas after the induction of either edematous or necrotizing pancreatitis. Four and 8 hours after induction of edematous and necrotizing pancreatitis, phospholipase A2-II mRNA expression in the rat pancreas was more or less unchanged, with strong upregulation of expression starting after 24 hours. In contrast, in a previous study in rats, phospholipase A2-II activity in the serum was already markedly increased within 24 hours of the onset of acute pancreatitis, 19, 50 suggesting that the source of phospholipase A2-II is extrapancreatic shortly after the initiation of the disease but is likely to be derived also from remaining viable pancreatic parenchyma during the later course.
In contrast to phospholipase A2-II, phospholipase A2-I mRNA expression in human pancreatitis was significantly decreased, indicating that during the course of acute pancreatitis, the synthesis of digestive enzymes is reduced, whereas mediators of inflammation, which normally have a restricted expression in the pancreas, are strongly upregulated.
When viewed together, these results suggest that both phospholipase A2-II and A2-IV might directly or indirectly influence or contribute to the inflammatory and morphologic changes in acute pancreatitis. The use of specific phospholipase A2 inhibitors in acute pancreatitis might allow downregulation of the phospholipase A2-regulated inflammatory cascades. 44, [51] [52] [53] This treatment concept has already been studied in rats, and the systemic application of specific phospholipase A2-II inhibitors decreases phospholipase A2-II activity, thereby reducing the extent of histologic damage in the pancreas. 19 However, whether these phospholipase A2-II inhibitors exert their influence on pancreatic or extrapancreatic phospholipase A2-II or both in the serum and in the tissue is not known and needs further evaluation.
In summary, we provide evidence that during acute pancreatitis, inflammatory mediators such as phospholipase A2-II and A2-IV are actively synthesized in the remaining viable pancreatic parenchyma, and they regulate and contribute to the pancreatic damage and systemic complications seen in this disorder.
